Trade

Watchlist

Portfolio

Message

Set Alert

BSE LIVE NSE LIVE 26 Aug, 2025 12:21 Volume Todays L/H More ×

Motilal Oswal's research report on Mankind Pharma

Mankind Pharma (MANKIND) delivered a largely in-line financial performance for 2QFY26. EBITDA was slightly lower than estimates due to higher employee costs. MANKIND undertook a restructuring exercise, including talent upgrade and an increase in the sales force, driving higher opex for the quarter. MANKIND continued to deliver industry-beating growth in domestic formulation (DF) for certain therapies such as cardiac and diabetes. The company also recorded healthy growth in in-licensed inhaler products for the quarter.

Outlook

We largely maintain our estimates for FY26/FY27/FY28. We value MANKIND at 42x 12M

See Full Page